|Control of glutamine metabolism by the tumor suppressor Rb.|
|Jump to Full Text|
|PMID: 23353822 Owner: NLM Status: MEDLINE|
|Retinoblastoma (Rb) protein is a tumor suppressor that is dysregulated in a majority of human cancers. Rb functions to inhibit cell cycle progression in part by directly disabling the E2F family of cell cycle-promoting transcription factors. Because the de novo synthesis of multiple glutamine-derived anabolic precursors is required for cell cycle progression, we hypothesized that Rb also may directly regulate proteins involved in glutamine metabolism. We examined glutamine metabolism in mouse embryonic fibroblasts (MEFs) isolated from mice that have triple knock-outs (TKO) of all three Rb family members (Rb-1, Rbl1 and Rbl2) and found that loss of global Rb function caused a marked increase in (13)C-glutamine uptake and incorporation into glutamate and tricarboxylic acid cycle (TCA) intermediates in part via upregulated expression of the glutamine transporter ASCT2 and the activity of glutaminase 1 (GLS1). The Rb-controlled transcription factor E2F-3 altered glutamine uptake by direct regulation of ASCT2 mRNA and protein expression, and E2F-3 was observed to associate with the ASCT2 promoter. We next examined the functional consequences of the observed increase in glutamine uptake and utilization and found that glutamine exposure potently increased oxygen consumption, whereas glutamine deprivation selectively decreased ATP concentration in the Rb TKO MEFs but not the wild-type (WT) MEFs. In addition, TKO MEFs exhibited elevated production of glutathione from exogenous glutamine and had increased expression of gamma-glutamylcysteine ligase relative to WT MEFs. Importantly, this metabolic shift towards glutamine utilization was required for the proliferation of Rb TKO MEFs but not for the proliferation of the WT MEFs. Last, addition of the TCA cycle intermediate α-ketoglutarate to the Rb TKO MEFs reversed the inhibitory effects of glutamine deprivation on ATP, GSH levels and viability. Taken together, these studies demonstrate that the Rb/E2F cascade directly regulates a major energetic and anabolic pathway that is required for neoplastic growth.|
|M R Reynolds; A N Lane; B Robertson; S Kemp; Y Liu; B G Hill; D C Dean; B F Clem|
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2013-01-28|
|Title: Oncogene Volume: 33 ISSN: 1476-5594 ISO Abbreviation: Oncogene Publication Date: 2014 Jan|
|Created Date: 2014-01-30 Completed Date: 2014-04-01 Revised Date: 2014-08-04|
Medline Journal Info:
|Nlm Unique ID: 8711562 Medline TA: Oncogene Country: England|
|Languages: eng Pagination: 556-66 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Amino Acid Transport System ASC / biosynthesis, genetics, metabolism
Biological Transport / genetics
E2F3 Transcription Factor / biosynthesis, metabolism*
Glutamate-Cysteine Ligase / biosynthesis
Glutaminase / biosynthesis, genetics, metabolism
Glutamine / metabolism*
Glutathione / biosynthesis
Ketoglutaric Acids / metabolism
Oxygen / metabolism
Promoter Regions, Genetic
RNA, Small Interfering
Reactive Oxygen Species / metabolism
Retinoblastoma Protein / genetics, metabolism*
Retinoblastoma-Like Protein p107 / genetics, metabolism*
Retinoblastoma-Like Protein p130 / genetics, metabolism*
|1P20RR18733/RR/NCRR NIH HHS; 3P20RR018733-09-BFC/BF/FDA HHS; P20 RR018733/RR/NCRR NIH HHS; R01 CA166327/CA/NCI NIH HHS; RR024489/RR/NCRR NIH HHS|
|0/Amino Acid Transport System ASC; 0/E2F3 Transcription Factor; 0/E2f3 protein, mouse; 0/Ketoglutaric Acids; 0/RNA, Small Interfering; 0/Rbl1 protein, mouse; 0/Rbl2 protein, mouse; 0/Reactive Oxygen Species; 0/Retinoblastoma Protein; 0/Retinoblastoma-Like Protein p107; 0/Retinoblastoma-Like Protein p130; 0/Slc1a5 protein, mouse; 0RH81L854J/Glutamine; 328-50-7/alpha-ketoglutaric acid; 8L70Q75FXE/Adenosine Triphosphate; EC 126.96.36.199/GLS1 protein, mouse; EC 188.8.131.52/Glutaminase; EC 184.108.40.206/Glutamate-Cysteine Ligase; GAN16C9B8O/Glutathione; S88TT14065/Oxygen|
Journal ID (nlm-journal-id): 8711562
Journal ID (pubmed-jr-id): 6325
Journal ID (nlm-ta): Oncogene
Journal ID (iso-abbrev): Oncogene
nihms-submitted publication date: Day: 28 Month: 1 Year: 2014
Electronic publication date: Day: 28 Month: 1 Year: 2013
Print publication date: Day: 30 Month: 1 Year: 2014
pmc-release publication date: Day: 30 Month: 7 Year: 2014
Volume: 33 Issue: 5
First Page: 556 Last Page: 566
PubMed Id: 23353822
|Control of Glutamine Metabolism By the Tumor Suppressor Rb|
|Miriam R. Reynolds125|
|Andrew N. Lane16|
|Bradford G. Hill124|
|Douglas C. Dean235|
|Brian F. Clem125*|
1Department of Medicine, University of Louisville, Louisville, KY
2Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY
3Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY
4Department of Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, Louisville, KY
5Department of Molecular Targets Group, University of Louisville, Louisville, KY
6Department of Structural Biology Program James Graham Brown Cancer Center, University of Louisville, Louisville, KY
|*Corresponding author: 505 S. Hancock St., CTRB, Rm. 422, University of Louisville, Louisville, KY 40202
Neoplastic cells are characterized by un-controlled proliferation which depends on their ability to increase cellular metabolism in order to produce the ATP and reducing power to drive the synthesis of macromolecules required for cell division (1). Dysregulated metabolism has been extensively studied for several decades, with the primary focus directed at the capacity of tumor cells to activate aerobic glycolysis (2–5). This metabolic alteration ultimately leads to increased glycolytic flux to lactate and a decrease in glucose carbon availability for the TCA cycle and other downstream biochemical processes. Accordingly, neoplastic cells require nutrient sources such as glutamine to replenish the anaplerotic carbon in the TCA cycle necessary to maintain their rapid cell division (6–8). In tumor cells, glutamine carbon is utilized for mitochondrial TCA cycling, glutathione synthesis, and fatty acid production (6, 9–12). Importantly, glutamine restriction or inhibitors of glutaminolytic enzymes decrease cell proliferation both in vitro and in vivo (7, 13–15). Although both the proto-oncogene MYC and the tumor suppressor p53 have been found to contribute to the control of glutamine uptake and glutaminolysis, the precise regulation of glutamine metabolism in human cancers is not fully understood (6, 16–20). The tumor suppressor, retinoblastoma protein (Rb), is a master regulator of several transcription factors involved in cell cycle regulation, yet the involvement of Rb pocket proteins in glutamine metabolism is unknown.
The Rb family of transcription factors (Rb-1, Rbl1, and Rbl2) has multiple inter-related target genes that converge on cell cycle regulators. Loss of Rb family function as a result of mutation or inactivating hyperphosphorylation by deregulated cyclin dependent kinases is a hallmark of all tumors, and understanding the full spectrum of Rb’s functions may enable the identification of proteins that can be targeted for the development of anti-cancer agents. The Rb family is classically believed to interact with the E2F transcription factors to regulate cell cycle progression. The Rb family members have over-lapping and compensatory functions and, as a result, genomic deletion of all three Rb family members (triple knockout, TKO) is required for the loss of cell cycle control in fibroblasts (21, 22). Beyond its role in cell cycle control, the Rb family regulates cell senescence in culture and cell contact inhibition and the TKO MEFs are thus immortal and lack cell contact inhibition (21, 22). Furthermore, Rb/E2F has been shown to have expanding roles including potentially linking cell proliferation to certain biochemical pathways (reviewed in (23)). Given that a dysfunctional Rb cascade promotes loss of proliferative control, we hypothesized that the Rb pathway also may directly regulate the uptake and conversion of glutamine into anabolic precursors that are required for neoplastic cell growth and survival.
Herein, we report that Rb family-deficient fibroblasts increase glutamine consumption to sustain mitochondrial function through anaplerosis and to maintain elevated intracellular glutathione. Importantly, elevated glutamine uptake is mediated through direct activity of specific E2F family members on glutaminolytic enzymes, and enhanced glutaminolysis is required for the growth and survival of Rb-dysfunctional cells. These data expand our understanding of the mechanisms by which tumor cells manipulate nutrient pathways to promote enhanced proliferation, and support the targeting of glutamine metabolism in Rb-deficient tumors as a potential therapeutic strategy.
Rb TKO cells contain genetic deletions of the three Rb family members (Rb1, Rbl1, and Rbl2) and exhibit several classic hallmarks of neoplastic cells including enhanced proliferation and immortalization (22). Initially, we examined basal 14C-glutamine uptake of Rb WT, Rb-1 null (Rb-1−/−), and Rb TKO mouse embryonic fibroblast (MEF) cells. Whereas Rb-1−/− cells exhibited a 4-fold increase in glutamine uptake, Rb TKO cells consumed 6-fold more 14C-glutamine relative to Rb WT MEFs (Fig. 1a). To confirm specificity of Rb-1 function in regulating glutamine uptake, Rb-1 was reconstituted in both the Rb-1−/− and TKO MEFs (Fig. 1b & Fig. S1a). As illustrated in Figure 1b, Rb-1 expression significantly suppressed glutamine uptake in both cell types with uptake in the Rb-1−/− cells relatively reduced to levels observed in the WT cells. These data indicate that although loss of Rb-1 function is sufficient to cause a marked increase in glutamine uptake in MEFs, Rbl1 and/or Rbl2 either can contribute to the suppression of glutamine uptake or can compensate for the loss of Rb-1 expression. Importantly, the entire Rb family can be suppressed by common mutations in human cancers (e.g. p16INK4A (24, 25)) and we thus elected to continue our studies on the metabolic effects of Rb dysfunction by directly comparing the Rb WT and the fully Rb-deficient TKO cells. To determine whether the observed increase in glutamine uptake was a regulated process, we examined mRNA expression of several glutamine transporters. The glutamine transporters ASCT2 and SLC38A5 previously have been identified to be elevated in tumor tissues and their expression has been demonstrated to be transcriptionally regulated by specific oncogenes (9, 26). In the Rb TKO cells, only ASCT2, and not SLC38A5, exhibited elevated mRNA levels compared to Rb WT cells and ASCT2 protein expression was found to be increased 6-fold in the Rb TKO cells (Fig. 1c). Consistent with a functional role of Rb-1 in regulating glutamine uptake, re-expression of Rb-1 also resulted in a marked decrease in ASCT2 expression (Fig. S1b). Examination of glutaminase (GLS) isoforms, which convert glutamine to glutamate, revealed that GLS1 mRNA is solely expressed in the MEF cells, but genetic deletion of the Rb family yielded no increase in GLS1 transcript levels (Fig. 1d). However, protein analysis revealed an increase in GLS1 expression (Fig. 1d), suggesting both transcriptional and post-transcriptional regulation of glutaminolytic enzymes by the Rb pathway. Given the increased GLS1 expression in Rb TKO cells, we expected that these cells would convert a greater portion of glutamine to glutamate and in doing so generate higher levels of ammonia, which is another product of GLS1 activity. As demonstrated in Figure 1e, NH4+ excretion was significantly higher in TKO compared to WT MEFs. To confirm these results and to identify specific glutamine-metabolic pathways within both WT and TKO MEFs, we conducted isotopomer analysis using [13C5,15N2]-glutamine by 2D-NMR. As shown in Figure 1f, TKO MEFs converted a relatively greater amount of extracellular glutamine to glutamate compared to WT MEFs. Together, these results demonstrate for the first time that genetic deletion of Rb family causes a direct induction of glutamine uptake and utilization by modulating specific enzymes involved in the glutaminolytic pathway.
To determine whether glutamine carbons enter the TCA cycle after conversion to glutamate, we next analyzed 13C incorporation into aspartate, which is generated from 13C-labeled oxaloacetate via activity of aspartate aminotransferase. We observed 63 ± 4.2% of aspartate carbon originated from glutamine in Rb TKO cells, whereas only 29 ± 2.4% was labeled in Rb WT cells (Fig. 2a). However, no labeling of lactate from glutamine was observed in the Rb TKO cells or in the medium (data not shown) suggesting that malic enzyme activity is low in these cells and glutamine carbon is preferentially metabolized to replenish TCA intermediates.
We also measured steady-state ATP levels and the rate of oxygen consumption by Rb WT and Rb TKO cells. Deletion of the Rb family resulted in 1.8-fold higher level of intracellular ATP (Fig. 2b), and an increase in the basal O2 consumption rate [OCR] (Fig. 2c). Furthermore, this increase in OCR was directly coupled to ATP production, with no differences in mitochondrial proton leak in the Rb TKO cells compared with WT cells (Fig. 2c). These measurements do not distinguish between the contribution of glutamine oxidation for mitochondrial function from oxidation of other carbon precursors such as glucose or fatty-acids. For this, we determined the baseline OCR in both cell types cultured in medium deprived of both glucose and glutamine and then measured the OCR response to the addition of exogenous glutamine (4 mM final concentration). Unlike WT MEFs, Rb TKO cells were able to enhance their O2 consumption with the addition of glutamine, indicating that cells devoid of Rb function can increase their mitochondrial metabolism by using glutamine carbon through TCA anaplerosis (Fig. 2d). Lastly, it is important to note that the increase in oxygen consumption and ATP levels observed in the Rb TKO cells could be a result of a greater number of mitochondria compared to the Rb WT cells. However, mitochondrial genome analysis revealed that Rb TKO cells contain significantly less mitochondria relative to WT cells (Fig. 2e). Together, these data suggest that the mitochondria in the TKO cells are more active, which is presumably attributable to the increase in the availability and capacity for glutamine metabolism.
Since Rb TKO cells exhibited elevated mitochondrial function relative to Rb WT cells, we postulated that the production of reactive oxygen species (ROS) such as superoxide and hydrogen peroxide would be significantly increased in the Rb-depleted cells. Based on DCF fluorescence, a higher percentage of TKO cells (60.3%) were positive for ROS formation compared to WT (13.5%) (Fig. 3a), and the mean fluorescence intensity was elevated in the Rb TKO cells (Fig. 3b). Furthermore, the rate of ROS production also was increased in the TKO cells (Fig. 3b). To determine mitochondrial ROS production within these cells, both Rb WT and Rb TKO cells were labeled with MitoSOX, which is an ROS indicator that is specifically targeted to the mitochondria (27). As illustrated in Figure 3c, Rb TKO cells generated significantly more mitochondrial ROS compared to Rb WT cells.
In addition to being a precursor for TCA anaplerosis, glutamine is the major carbon source for glutathione biosynthesis in multiple cell systems (9, 10). To determine whether Rb suppresses glutathione production, we initially measured total glutathione levels, and found that Rb TKO cells have significantly elevated glutathione compared to WT cells (Fig. 3d). This was further confirmed by metabolomics analysis with 13C-glutamine, whereby Rb TKO cells exhibited an increase in labeled glutamine incorporation into GSH (Fig. S2a&b). We also found that this increase is likely driven in part by elevated expression of gamma-glutamylcysteine ligase (GCLC) in the Rb TKO cells, which is the rate-limiting step in glutathione synthesis (Fig. 3e). However, an increase in GSSG formation within the TKO cells resulted in a decrease in the levels of reduced glutathione (GSH) to total glutathione in the Rb TKO cells (Fig 3f). Together, these data suggest that Rb-deficient cells not only increase glutamine metabolism to provide the anaplerotic carbon for enhanced mitochondrial function, but also the synthesis of glutathione.
Our results demonstrate that loss of Rb function enhanced glutamine metabolism for both mitochondrial metabolism and glutathione production, two pathways necessary for the growth and survival of neoplastic cells. In order to determine the relative dependence of Rb WT versus Rb TKO cells on glutamine, we next cultured the cells in the absence of glutamine and quantified the viable cell number over 48 hours. We found that the growth of Rb WT cells was relatively unaffected by glutamine withdrawal even after 48 hours, whereas Rb TKO cells were unable to survive and grow in the absence of glutamine (Fig. 4a). In addition, while siRNA-mediated suppression of either ASCT2 or GLS1 reduced glutamine uptake and NH4+ secretion in both the WT and Rb TKO MEFs, only the growth of the Rb TKO cells was negatively affected (Fig. S3). These results further highlight the potential utility of small molecule antagonists of these enzymes as anti-cancer agents in Rb-deficient tumors. Interestingly, suppression of GLS1 resulted in a significant reduction in glutamine uptake in these cells. While the mechanism by which GLS1 suppression is able to decrease glutamine uptake is not well defined, inhibition of primary metabolizing enzymes within other biochemical pathways have previously been observed to inhibit nutrient uptake (for example, effects of inhibition of HK2 and choline kinase on glucose and choline transport, respectively) (28, 29). Furthermore, in support of the requirement of glutamine for maintaining the energetic requirements for elevated proliferation, glutamine withdrawal also resulted in a rapid decrease in steady-state ATP levels (3 hrs.), while ATP levels were unchanged until 48 hours in Rb WT cells under the same conditions (Fig. 4b). We then supplemented the medium with cell permeable α-ketoglutarate (α-kg), a TCA cycle intermediate, and observed a significant rescue in ATP levels as well as cytotoxicity caused by glutamine withdrawal in the Rb TKO cells (Fig. 5a&b). Furthermore, consistent with glutamine being the primary carbon source for glutathione biosynthesis and the observation that Rb TKO cells increase glutamine carbon incorporation into GSH (Figure S2), glutamine depletion significantly decreased GSH levels and resulted in an overall increase in cellular ROS production in the Rb TKO cells (Fig 5c–e). Similar observations have been reported in which small molecule inhibition of GLS1 resulted in lower GSH levels and a concomitant increase in ROS levels in lymphoma cells (10). However, addition of α-kg decreased ROS levels and resulted in partial rescue of GSH levels in the Rb TKO cells (Fig 5c–e). Combined, our data indicate that deletion of the Rb pathway directly stimulates glutamine utilization in order to provide the energy and macromolecular precursors necessary for enhanced cell division and survival.
The Rb family is known to negatively regulate gene expression through direct interaction with E2F family members, and Rb functions to suppress the activity of E2F-1, 2, and -3 to transcriptionally activate downstream target genes (24). To determine if these E2F members were altered in the absence of the Rb family, we examined the level of expression of each member between Rb WT and Rb TKO cells. Both E2F-1 and E2F-2 mRNA (data not shown) and protein expression were significantly elevated in the TKO cells, whereas E2F-3 levels exhibited little change (Fig. 6a). Since our analysis of the Rb WT and Rb TKO cells examined the effects of Rb dysfunction on glutaminolysis, we sought to determine whether any of these E2F family members played a role in mediating these alterations in the Rb TKO cells. We transfected the cells with E2F-1, -2, and -3 siRNA and measured the expression of ASCT2 and GLS1. We found that only E2F-3 knock-down significantly decreased ASCT2 expression, whereas there was no effect on GLS1 levels by siRNA against any E2F member (Fig. 6b). These results are not surprising since ASCT2, but not GLS1, was found to be transcriptionally regulated in the absence of Rb (Fig. 1b). Interestingly, inhibition of the expression of E2F members revealed differential effects on glutamine consumption in Rb TKO cells, in which E2F-2 and E2F-3 decreased uptake by 20 and 35%, respectively, while E2F-1 yielded no significant difference (Fig. 6d). However, E2F-1 and E2F-3 siRNA reduced cell proliferation, while E2F-2 suppression did not significantly alter Rb TKO cell growth (Fig. 6c). These differential effects on glutamine uptake and cell growth by E2F proteins suggest that their regulatory involvement in multiple cellular pathways, be it cell cycle or metabolic control or both, cumulatively determine the extent of their influence on cell proliferation. Next, chromatin immunoprecipitation analysis was performed to assess the potential for direct regulation of E2Fs on ASCT2 gene expression. Using antibodies specific for each E2F family member, E2F-3 was observed to significantly associate with the proximal ASCT2 promoter (Fig. 6e). ChIP analysis of E2F-1,-2, and -3 binding to a known target gene promoter, cdc2 (30), was performed to assess specificity of E2F association to the ASCT2 promoter. As illustrated in Figure 6e, under these conditions, all three E2F proteins associated with the cdc2 promoter, with E2F-1 and E2F-3 exhibiting the strongest interaction. In addition, as a negative control, none of the E2F family members were found to interact with the GAPDH gene promoter (Fig. 6e), as has been previously demonstrated for E2F-1 in the Rb TKO cells (31). These results correlate with our protein and glutamine uptake analysis in that E2F-3 suppression alone decreased ASCT2 expression and had a significant effect on glutamine consumption. Taken together, these results indicate that the Rb pathway regulates glutamine metabolism for mitochondrial function and glutathione synthesis partially through direct control of glutamine uptake via specific E2F mediated transcription of target genes, such as ASCT2, and partly through unknown alternative regulatory mechanisms (i.e. post-transcriptional – GLS1) of proteins involved in glutaminolysis (Fig. 7).
In the current study, we have found that genomic deletion of all three Rb family members causes a shift towards enhanced glutamine metabolism in part via the glutamine transporter ASCT2 and GLS1 that in turn leads to dependence on glutamine for cell proliferation and survival. Importantly, reconstitution of Rb-1 in the Rb-dysfunctional cells decreased glutamine uptake and suppressed ASCT2 expression. We also have found that Rb TKO MEFs, and not the WT MEFs, metabolize glutamine to increase mitochondrial function, ATP production and glutathione synthesis. Furthermore, the elevated ATP and ROS production observed in the Rb TKO cells was not due to greater mitochondrial mass since real-time PCR analysis revealed a reduction in the ratio of mitochondrial to nuclear DNA (Fig 2e) indicating that the mitochondria in Rb TKO MEFs are more metabolically active. This is in contrast to previous reports in normal differentiated adipocytes, where genomic loss of Rb-1 resulted in increased energy expenditure due to a significant increase in mitochondrial copy number (32). This discrepancy is unclear, yet may be due to multiple factors including cell type as well as extent of Rb pathway dysfunction. Taken together, our analysis on the effects of Rb loss and re-expression combined with our examination of direct E2F promoter occupancy support a direct role for the Rb pathway in regulating cell glutaminolysis.
Our analysis of E2F function on glutamine metabolism suggests that the E2F family members may regulate several independent but required cellular processes. E2F-3 suppression reduced both cell number and glutamine uptake and was functionally linked to the promoter of ASCT2. In addition, E2F-2 partially decreased glutamine uptake, yet suppression of E2F-2 expression yielded no effect on ASCT2 or GLS1 levels. These data indicate that there may be other Rb pathway regulated enzymes, beyond ASCT2, SLC38A5, and GLS1/2, that may contribute to the overall alteration in glutaminolysis driven by Rb dysfunction. E2F-1 knock-down significantly decreased cell proliferation in the Rb TKO cells yet had little effect on glutamine uptake. The effect on cell growth of Rb TKO cells mediated by E2F-1 siRNA could be due to its extensive involvement in regulating cell cycle mediators. However, a recent report has revealed that E2F-1 can enhance mitochondrial function through direct transcriptional regulation of multiple enzymes involved in oxidative phosphorylation (33). This alteration may, in turn, promote mitochondrial metabolism of available glutamine-derived carbon that is generated through the activities of E2F-3 and/or E2F-2 regulated protein targets. Furthermore, the Rb/E2F-1 cascade also has been observed to regulate the conversion of pyruvate to acetyl-CoA by directly modulating the expression of PDK4, which controls the activity of pyruvate dehydrogenase (34). These observations suggest that loss of Rb function may suppress the flux of glucose-derived carbons into the TCA cycle which, in turn, may increase reliance on alternative sources of anaplerotic carbon. Indeed, our data complement these results by extending the regulatory function of the Rb cascade to glutamine uptake and metabolism and by providing support for E2F members involved in suppressing this metabolic activity. Based on these new results, we believe that the ability of the Rb pathway to tightly regulate cellular growth not only stems from its well-known role in modulating cell cycle checkpoints, but also from its direct metabolic control of ATP and macromolecule production.
The Rb WT and Rb TKO cells are isogenic apart from genomic deletion of all three Rb family members (22). The Rb family contains three distinct members, and are known to exhibit overlapping functions (35). This compensatory activity was evident with respect to glutamine uptake wherein Rb-1−/− MEFs exhibited a 4-fold increase in glutamine uptake compared to WT MEFs, whereas a 6-fold increase was observed in the Rb TKO MEFs (Fig. 1a). While the Rb TKO MEFs were used to examine the complete loss of Rb function on glutamine metabolism, these data indicate that Rbl1 and/or Rbl2 also may play a role in regulating glutamine metabolism. Traditionally, the Rbl1 and Rbl2 members do not associate with the activator E2Fs, but interact primarily with E2F-4 or -5 (24). This, in turn, suggests that these E2Fs may also function to tether these Rb proteins to target genes involved in mediating glutaminolysis. However, Rbl1 has recently been observed to specifically control E2F-3 activity in regulating target gene expression (36). Since the independent regulatory mechanisms by Rb-1, Rbl1, and Rbl2 on glutamine metabolism remain unclear, the elucidation of the distinct contributions of each Rb family member and their respective E2F partners in mediating glutamine metabolism is a focus of on-going studies. That genomic deletion of all three Rb family members caused an established cancer-related metabolic shift to glutamine dependency strongly supports the conclusion that the Rb pathway has a previously under-recognized role in the regulation of cellular metabolism. Whether the metabolic effects observed in this study are due solely to direct Rb/E2F control on metabolic target genes or through additional downstream mediators whose expression is also altered by loss of Rb remains to be determined.
Genetic deletion or mutation of Rb is present in 100% of retinoblastomas, 90% of small cell lung carcinomas as well as in cancers of the bladder (70%), prostate (60%), liver (40%), and breast (30%) (25). Additionally, dysfunctional Rb extends to other cancer types, such as pancreatic (70%), colorectal (60%), and melanoma (60%), wherein the Rb family is inactivated by hyperphosphorylation by deregulated CDKs. Cumulatively, these frequencies suggest that therapies targeting the glutaminolytic pathway may be effective against a broad spectrum of tumor types. Indeed, inhibitors of GLS1, such as BPTES, are being utilized in pre-clinical settings, and have been shown to be effective in tumor xenograft models (10, 15, 37). Using in silico drug discovery methodologies (38, 39), we intend to identify novel small molecule antagonists of these enzymes for testing as anti-cancer agents. Additionally, the functional status of the Rb/E2F pathway in specific tumors may serve as a key biomarker that may predict responsiveness to these agents. We conclude that the ability of the Rb family to suppress glutamine metabolism contributes to its tumor suppressor activity and that these studies may identify novel targets for the development of anti-neoplastic therapies.
Retinoblastoma protein family triple knock-out mouse embryonic fibroblasts (TKO MEFs) or Rb-1 null MEFs were generated as previously described (22). MEFs were cultured in DMEM (Gibco) supplemented with 10% FBS (Hyclone), 25mM glucose, 4mM glutamine and 50µg/mL gentamicin sulfate. Cells were maintained at 5% CO2 at 37°C.
WT, Rb-1−/−or TKO MEFs were washed and supplemented with 1 µM [U-14C]-glutamine for 5 minutes. Medium was aspirated, and cells were washed three times with glutamine deficient media. Sample c.p.m. was acquired on a liquid scintillation counter.
RNA was obtained from three separate preparations of WT and TKO MEFs using the RNeasy kit (Qiagen). Gene expression was determined using specific Taqman Gene Expression Assays (ABI) on a Step One Plus RT-PCR system.
Western analysis was done on protein lysates from WT and TKO MEFs using antibodies against ASCT2 (Cell Signaling), GLS1 (Abnova), GCLC (ThermoScientific), E2F-1 (Cell Signaling), E2F-2 (Santa Cruz), E2F-3 (Santa Cruz), and β-actin (Pierce). Densitometry analysis was performed using Quantity One software.
Medium ammonia levels were determined using the Ammonia Assay Kit (Biovision). Secretion rate is presented as nmol / min / mg protein from triplicate samples from two independent experiments.
WT and TKO cells were seeded at 1 × 106 cells in 15 centimeter dishes. MEFs were then labeled for two cell doublings (WT: 60 hours, TKO: 48 hours) with DMEM supplemented with 25mM glucose, 10% dialyzed FBS, and 4mM [13C5,15N2]-glutamine. Metabolites were extracted twice with 10% TCA, and pooled extracts were then flash-frozen in LN2 and lyophilized. In order to resolve 13C-glutamine incorporation into glutamine (Q), glutamate (E), and GSH, a separate protocol for cell metabolite extraction under neutral pH was also performed as previously described (40). In both protocols, NMR spectra were recorded as described previously (38).
A Seahorse Bioscience XF24 Extracellular Flux Analyzer was used to measure oxygen consumption in intact cells as described previously (41–43). The assay media consisted of DMEM supplemented with 25mM glucose and 4mM glutamine. In other studies, oxygen consumption was measured in WT and TKO MEFs cultured before and after addition of exogenous 4mM glutamine. ATP concentrations were determined using the ATP Determination Kit (Invitrogen).
The ratio of mitochondrial to nuclear DNA was determined by real-time PCR using two sets of primers specific for either the mitochondrial or nuclear genome as previously described (32, 44). Real-time PCR was performed on serial dilutions of four separate cell DNA preparations in triplicate measurements.
Total, reduced and oxidized glutathione levels were determined in cell lysates by using the Glutathione Assay Kit (Biovision), the GSH-GLO and GSSG/GSG-GLO Assay Kits (Promega). Data are presented as normalized total glutathione and the ratio of GSH to total glutathione between WT and TKO MEFs, or relative GSH levels in the TKO MEFs.
ROS production in WT and TKO MEFs was determined by DCF-DA (Invitrogen) fluorescence by flow cytometry or by a SpectraMax Fluorometer (Molecular Probes). Mitochondrial ROS was measured by MitoSOX fluorescence by flow cytometry.
WT and TKO MEFs were plated in 12-well plates, and 16 hours post-seeding, media was replaced with either complete DMEM or DMEM without glutamine. Cell number and viability was determined by trypan blue exclusion and enumeration using a hemocytometer at 3, 6, 24, & 48 hours after media change. For alpha-ketoglutarate add-back experiments, 7 mM dimethyl-alpha-ketoglutarate was added concurrent with media change.
Cells were transfected with a plasmid encoding mouse Rb-1 (Origene: MG227287) using JetPrime reagent following manufacturer’s protocol (Polyplus). siRNA transfections were performed as previously described (39) and the following siRNAs were used: E2F-1: (Ambion: #s201266); E2F-2: (Ambion: #s109846); E2F-3: (Ambion: #s65238). Cell number, protein expression, and glutamine uptake were analyzed either 48 or 72 hours post-transfection as described above.
ChIP assays were performed according to manufacturer’s protocol with minor modifications (Cell Signaling). ChIP was performed with antibodies raised against IgG (Cell Signaling), E2F-1 (Cell Signaling), E2F-2 (Santa-Cruz), and E2F-3 (Santa Cruz). Eluted chromatin was subjected to real-time PCR quantification for the mouse ASCT2, cdc2, and GAPDH promoters using specific primers (listed in supplementary material).
Statistical significance for glutamine uptake, mRNA & protein expression, ammonia secretion, glutathione levels, ROS production, viable cell number, and ATP production between WT and TKO MEFs was determined by a two-sample, nonparametric, two-tailed t-test using Graph Pad Prism. p < 0.05 was considered to be statistically significant.
FN1Conflict of Interest
The authors state that there are no conflicts of interests with respect to these studies.
FN2Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
The authors gratefully acknowledge Jason Chesney, Sucheta Telang, and John Eaton for their insightful discussions, and thank Tyler Jacks for the kind gift of the TKO MEFs. NMR experiments were carried out at the James Graham Brown Cancer Center NMR facility, supported in part by the Brown Foundation and NCCRR grant 1P20 RR18733. This work was supported by a Center of Biomedical Research Excellence in Molecular Targets (3P20RR018733-09) grant from the National Center for Research Resources and by RR024489 (BGH).
|1.||Hanahan D,Weinberg RA. Hallmarks of cancer: the next generationCellYear: 2011Month: 3 Day: 4 144564667421376230|
|2.||Dang CV,Lewis BC,Dolde C,Dang G,Shim H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosisJ Bioenerg BiomembrYear: 1997Month: 8 2943453549387095|
|3.||Gillies RJ,Robey I,Gatenby RA. Causes and consequences of increased glucose metabolism of cancersJ Nucl MedYear: 2008Month: 6 49Suppl 224S42S18523064|
|4.||Moreno-Sanchez R,Rodriguez-Enriquez S,Marin-Hernandez A,Saavedra E. Energy metabolism in tumor cellsFEBS JYear: 2007Month: 3 27461393141817302740|
|5.||Warburg O,Negelein E. On the metabolism of cancer cellsBiochemische ZeitschriftYear: 1924152319344|
|6.||DeBerardinis RJ,Mancuso A,Daikhin E,Nissim I,Yudkoff M,Wehrli S,et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesisProc Natl Acad Sci U S AYear: 2007Month: 12 Day: 4 10449193451935018032601|
|7.||Yuneva M,Zamboni N,Oefner P,Sachidanandam R,Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cellsJ Cell BiolYear: 2007Month: 7 Day: 2 17819310517606868|
|8.||Gao P,Tchernyshyov I,Chang TC,Lee YS,Kita K,Ochi T,et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolismNatureYear: 2009Month: 4 Day: 9 458723976276519219026|
|9.||Wise DR,DeBerardinis RJ,Mancuso A,Sayed N,Zhang XY,Pfeiffer HK,et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addictionProc Natl Acad Sci U S AYear: 2008Month: 12 Day: 2 10548187821878719033189|
|10.||Le A,Lane AN,Hamaker M,Bose S,Gouw A,Barbi J,et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cellsCell MetabYear: 2012Month: 1 Day: 4 15111012122225880|
|11.||Metallo CM,Gameiro PA,Bell EL,Mattaini KR,Yang J,Hiller K,et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxiaNatureYear: 2011Month: 1 Day: 19 481738138038422101433|
|12.||Mullen AR,Wheaton WW,Jin ES,Chen PH,Sullivan LB,Cheng T,et al. Reductive carboxylation supports growth in tumour cells with defective mitochondriaNatureYear: 2011Month: 1 Day: 19 481738138538822101431|
|13.||Gaglio D,Soldati C,Vanoni M,Alberghina L,Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblastsPLoS OneYear: 200943e471519262748|
|14.||Lora J,Alonso FJ,Segura JA,Lobo C,Marquez J,Mates JM. Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cellsEur J BiochemYear: 2004Month: 11 271214298430615511236|
|15.||Seltzer MJ,Bennett BD,Joshi AD,Gao P,Thomas AG,Ferraris DV,et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1Cancer ResYear: 2010Month: 11 Day: 15 70228981898721045145|
|16.||Dang CV,Le A,Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunitiesClin Cancer ResYear: 2009Month: 11 Day: 1 15216479648319861459|
|17.||Dang CV,O'Donnell KA,Zeller KI,Nguyen T,Osthus RC,Li F. The c-Myc target gene networkSemin Cancer BiolYear: 2006Month: 8 16425326416904903|
|18.||Bensaad K,Tsuruta A,Selak MA,Vidal MN,Nakano K,Bartrons R,et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosisCellYear: 2006Month: 7 Day: 14 126110712016839880|
|19.||Hu W,Zhang C,Wu R,Sun Y,Levine A,Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant functionProc Natl Acad Sci U S AYear: 2010Month: 4 Day: 20 107167455746020378837|
|20.||Matoba S,Kang JG,Patino WD,Wragg A,Boehm M,Gavrilova O,et al. p53 regulates mitochondrial respirationScienceYear: 2006Month: 6 Day: 16 31257801650165316728594|
|21.||Dannenberg JH,van Rossum A,Schuijff L,te Riele H. Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditionsGenes DevYear: 2000Month: 12 Day: 1 14233051306411114893|
|22.||Sage J,Mulligan GJ,Attardi LD,Miller A,Chen S,Williams B,et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalizationGenes DevYear: 2000Month: 12 Day: 1 14233037305011114892|
|23.||Takahashi C,Sasaki N,Kitajima S. Twists in views on RB functions in cellular signaling, metabolism and stem cellsCancer SciYear: 2012Month: 3 Day: 26|
|24.||Classon M,Harlow E. The retinoblastoma tumour suppressor in development and cancerNat Rev CancerYear: 2002Month: 12 21291091712459729|
|25.||Knudsen ES,Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic responseNat Rev CancerYear: 2008Month: 9 8971472419143056|
|26.||Fuchs BC,Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?Semin Cancer BiolYear: 2005Month: 8 15425426615916903|
|27.||Liu M,Liu H,Dudley SC Jr. Reactive oxygen species originating from mitochondria regulate the cardiac sodium channelCirc ResYear: 2010Month: 10 Day: 15 107896797420724705|
|28.||Clem BF,Clem AL,Yalcin A,Goswami U,Arumugam S,Telang S,et al. A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signalingOncogeneYear: 2011Month: 7 Day: 28 30303370338021423211|
|29.||Kim JW,Gao P,Liu YC,Semenza GL,Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1Mol Cell BiolYear: 2007Month: 11 27217381739317785433|
|30.||Wells J,Boyd KE,Fry CJ,Bartley SM,Farnham PJ. Target gene specificity of E2F and pocket protein family members in living cellsMol Cell BiolYear: 2000Month: 8 20165797580710913163|
|31.||Liu Y,Costantino ME,Montoya-Durango D,Higashi Y,Darling DS,Dean DC. The zinc finger transcription factor ZFHX1A is linked to cell proliferation by Rb-E2F1Biochem JYear: 2007Month: 11 Day: 15 4081798517655524|
|32.||Dali-Youcef N,Mataki C,Coste A,Messaddeq N,Giroud S,Blanc S,et al. Adipose tissue-specific inactivation of the retinoblastoma protein protects against diabesity because of increased energy expenditureProc Natl Acad Sci U S AYear: 2007Month: 6 Day: 19 10425107031070817556545|
|33.||Blanchet E,Annicotte JS,Lagarrigue S,Aguilar V,Clape C,Chavey C,et al. E2F transcription factor-1 regulates oxidative metabolismNat Cell BiolYear: 2011Month: 9 1391146115221841792|
|34.||Hsieh MC,Das D,Sambandam N,Zhang MQ,Nahle Z. Regulation of the PDK4 isozyme by the Rb-E2F1 complexJ Biol ChemYear: 2008Month: 10 Day: 10 28341274102741718667418|
|35.||Dannenberg JH,Schuijff L,Dekker M,van der Valk M,te Riele H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130Genes DevYear: 2004Month: 12 Day: 1 18232952296215574596|
|36.||McClellan KA,Vanderluit JL,Julian LM,Andrusiak MG,Dugal-Tessier D,Park DS,et al. The p107/E2F pathway regulates fibroblast growth factor 2 responsiveness in neural precursor cellsMol Cell BiolYear: 2009Month: 9 29174701471319564414|
|37.||Wang JB,Erickson JW,Fuji R,Ramachandran S,Gao P,Dinavahi R,et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformationCancer CellYear: 2010Month: 9 Day: 14 18320721920832749|
|38.||Clem B,Telang S,Clem A,Yalcin A,Meier J,Simmons A,et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growthMol Cancer TherYear: 2008Month: 1 7111012018202014|
|39.||Clem BF,Clem AL,Yalcin A,Goswami U,Arumugam S,Telang S,et al. A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signalingOncogeneYear: 2011Month: 3 Day: 21|
|40.||Fan TW,Lane AN,Higashi RM,Yan J. Stable isotope resolved metabolomics of lung cancer in a SCID mouse modelMetabolomicsYear: 2011Month: 6 Day: 1 7225726921666826|
|41.||Dranka BP,Benavides GA,Diers AR,Giordano S,Zelickson BR,Reily C,et al. Assessing bioenergetic function in response to oxidative stress by metabolic profilingFree Radic Biol MedYear: 2011Month: 11 Day: 1 5191621163521872656|
|42.||Hill BG,Dranka BP,Zou L,Chatham JC,Darley-Usmar VM. Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenalBiochem JYear: 2009Month: 11 Day: 15 42419910719740075|
|43.||Perez J,Hill BG,Benavides GA,Dranka BP,Darley-Usmar VM. Role of cellular bioenergetics in smooth muscle cell proliferation induced by platelet-derived growth factorBiochem JYear: 2010Month: 6 Day: 1 428225526720331438|
|44.||Ciavarra G,Zacksenhaus E. Rescue of myogenic defects in Rb-deficient cells by inhibition of autophagy or by hypoxia-induced glycolytic shiftJ Cell BiolYear: 2010Month: 10 Day: 18 191229130120937698|
Keywords: Retinoblastoma Protein, Metabolism, Glutamine, Cancer, Tumor Suppressor.
Previous Document: Cystathionase mediates senescence evasion in melanocytes and melanoma cells.
Next Document: MicroRNAs and the genetic network in aging.